Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy by harnessing the body's immune system to target ...

Explore the potential of gene therapy as a groundbreaking approach to curing diseases, beyond traditional pharmacological ...

In 2024, AbbVie’s presentation at the conference focused on its recent acquisitions of ImmunoGen and Cerevel. AbbVie paid ...

Researchers identify stem cell–based molecular subtypes that improve prognosis prediction in colorectal cancer and support ...

A new CRISPR approach can control genes without cutting DNA, opening a safer path for treating genetic diseases. A newly ...

Immense progress in gene editing, drug discovery and conservation are just some of the reasons to be cheerful about 2025 ...

Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).

Explore how nanotechnology acts as the 'Convergence Engine' for AI materials discovery, CRISPR gene therapy delivery, and ...

Rb1 loss may serve as a predictive biomarker to guide new targeted therapies for select breast cancers resistant to standard ...

The CLL17 trial showed noninferiority of fixed-duration regimens compared to continuous BTK inhibitor therapy, highlighting ...

China NMPA grants marketing approval for Innovent Biologics' Tyvyt, a CTLA-4 monoclonal antibody: San Francisco Saturday, December 27, 2025, 16:00 Hrs [IST] Innovent Biologics Inc ...

A team led by investigators at Mass General Brigham and Dana-Farber Cancer Institute has developed and validated an ...